Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update

Lynn Henry, N.; R. Somerfield, Mark; Dayao, Zoneddy; Elias, Anthony; Kalinsky, Kevin; M. McShane, Lisa; Moy, Beverly; Ho Park, Ben; M. Shanahan, Kelly; Sharma, Priyanka; Shatsky, Rebecca; Stringer-Reasor, Erica; L. Telli, Melinda; C. Turner, Nicholas; DeMichele, Angela

doi:10.1200/jco.22.01063

Public

Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update

Published in Journal of Clinical Oncology • Jun 27, 2022

Authors:

N. Lynn Henry

Mark R. Somerfield

Zoneddy Dayao

Abstract

PURPOSE To update the ASCO Biomarkers to Guide Systemic Therapy for Metastatic Breast Cancer (MBC) guideline. METHODS An Expert Panel conducted a systematic review to identify randomized clinical trials and prospective-retrospective studies from January 2015 to January 2022. RESULTS The search ident...

Subject

Medicine

PARP inhibitor

Oncology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!